Compare · ABT vs TEVA
ABT vs TEVA
Side-by-side comparison of Abbott Laboratories (ABT) and Teva Pharmaceutical Industries Limited (TEVA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and TEVA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $154.95B, about 4.2x TEVA ($37.05B).
- Over the past year, ABT is down 32.3% and TEVA is up 98.4% - TEVA leads by 130.7 points.
- ABT has been more active in the news (10 items in the past 4 weeks vs 5 for TEVA).
- Both have 25 recent analyst ratings on file.
- Company
- Abbott Laboratories
- Teva Pharmaceutical Industries Limited
- Price
- $88.95-3.44%
- $31.82-1.18%
- Market cap
- $154.95B
- $37.05B
- 1M return
- -0.77%
- -7.87%
- 1Y return
- -32.34%
- +98.38%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 10
- 5
- Recent ratings
- 25
- 25
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system and pain area include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. The company was founded in 1901 and is based in Tel Aviv-Yafo, Israel.
Latest ABT
- SEC Form 4 filed by Director Stratton John G
- SEC Form 4 filed by Director Roman Michael F
- SEC Form 4 filed by Director Gonzalez Patricia Paola
- SEC Form 4 filed by Director Conroy Kevin T
- SEC Form 4 filed by Director Ahuja Nita
- EXECUTIVE VICE PRESIDENT Morrone Louis H. covered exercise/tax liability with 269 units of Common shares without par value, decreasing direct ownership by 0.35% to 76,574 units (SEC Form 4)
- Robert W. Baird initiated coverage on Abbott Labs with a new price target
- EVP, GC AND SECRETARY Cushman Elizabeth C. covered exercise/tax liability with 560 units of Common shares without par value, decreasing direct ownership by 1% to 38,013 units (SEC Form 4)
- Abbott hosts conference call for second-quarter earnings
- ALZpath Signs Global Licensing Agreement with Abbott to Advance Blood-Based Alzheimer's Disease Testing
Latest TEVA
- Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis
- Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis
- Teva and Samsung Bioepis Enter Commercialization Agreement for OPUVIZ®, a Biosimilar Referencing Eylea® (aflibercept), in Canada
- Teva to Advance Its Anti-IL-15 Antibody, Designed for Quarterly Dosing, Into Phase 2b Development in Vitiligo, Following Encouraging Phase 1b Results
- EVP, Global Operations Shields Matthew sold $321,547 worth of Ordinary Shares (9,989 units at $32.19), closing all direct ownership in the company (SEC Form 4)
- Teva Releases Q2 2026 Aide Memoire
- Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome
- Teva to Host Conference Call to Discuss Second Quarter 2026 Financial Results on July 29, 2026 at 8 a.m. ET
- EVP, Chief Financial Officer Kalif Eliyahu Sharon sold $3,633,308 worth of Ordinary Shares (106,563 units at $34.10) as part of a pre-agreed trading plan, decreasing direct ownership by 62% to 65,621 units (SEC Form 4)
- Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategy